Published Technical Disclosure Archive

Enhanced Multimodal Chromatography Method for HIV-1 Envelope Glycoprotein Purification

Publication ID: 24-11857619_0006_PTD
Published: October 28, 2025
Category:Direct Improvements & Enhancements

Legal Citation

pr1or.art Inc., “Enhanced Multimodal Chromatography Method for HIV-1 Envelope Glycoprotein Purification,” Published Technical Disclosure No. 24-11857619_0006_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857619_0006_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,619.

Summary of the Inventive Concept

An improved multimodal chromatography method for purifying HIV-1 envelope glycoprotein, enabling higher yields, improved purity, and enhanced process efficiency through real-time monitoring and optimized purification conditions.

Background and Problem Solved

The original patent (Multimodal chromatography method for the purification of HIV-1 envelope glycoprotein) has limitations in terms of yield, purity, and process efficiency. The new inventive concept addresses these limitations by introducing real-time monitoring, optimized purification conditions, and a combination of anion exchange and hydrophobic interaction chromatography resins.

Detailed Description of the Inventive Concept

The enhanced multimodal chromatography method comprises a multimodal chromatography column and a control module for optimizing purification conditions based on real-time monitoring of protein elution profiles. The method involves capturing the HIV-1 envelope glycoprotein on a multimodal resin, washing the resin with a buffer solution having a controlled ionic strength, and eluting the protein with a buffer solution having a controlled pH and ionic strength. The combination of anion exchange and hydrophobic interaction chromatography resins enables higher yields and improved purity. The control module optimizes the buffer composition, pH, and ionic strength to minimize protein aggregation and maximize yield.

Novelty and Inventive Step

The new inventive concept introduces the use of real-time monitoring, optimized purification conditions, and a combination of anion exchange and hydrophobic interaction chromatography resins, which are not present in the original patent. These novel features enable higher yields, improved purity, and enhanced process efficiency.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept include using different types of multimodal resins, varying the buffer composition and pH, and incorporating additional purification steps. Variations of the control module could include different algorithms for optimizing purification conditions and integrating with different types of chromatography systems.

Potential Commercial Applications and Market

The enhanced multimodal chromatography method has significant commercial potential in the biotechnology and pharmaceutical industries, particularly in the development of HIV vaccines and therapeutics. The improved yield, purity, and process efficiency of the inventive concept make it an attractive solution for large-scale production of HIV-1 envelope glycoprotein.

CPC Classifications

SectionClassGroup
A A61 A61K39/21
C C07 C07K1/18
C C07 C07K14/005
C C07 C07K14/162
C C12 C12N7/02
A A61 A61K2039/53
C C12 C12N2740/16051
C C12 C12N2740/16111
C C12 C12N2740/16122
C C12 C12N2740/16134

Field of Art

Biotechnology and protein purification, specifically focused on HIV envelope glycoprotein isolation techniques, requiring expertise in chromatography, protein chemistry, and molecular biology with advanced degrees and practical experience in protein purification methods

Person of Ordinary Skill (PHOSITA) Profile

A PhD-level biochemist or molecular biologist with 3-5 years of specialized experience in protein purification techniques, familiar with multimodal chromatography, protein separation strategies, and analytical instrumentation

Obviousness Rationale

A PHOSITA would recognize that the PTD's enhanced multimodal chromatography method represents predictable variations on the source patent's fundamental approach, utilizing known chromatographic techniques and optimization strategies that would be apparent to a skilled practitioner seeking incremental improvements in protein purification processes.

Obvious Combinations & Variations

Source Patent Element
Multimodal resin-based capture of HIV-1 gp140 protein
PTD Variation
Adding real-time monitoring and control module for optimizing purification conditions
Obviousness Reasoning
Implementing process control and monitoring is a standard engineering approach for improving chromatographic separations, representing a predictable enhancement to existing purification techniques
Source Patent Element
Flow-through mode multimodal chromatography
PTD Variation
Combining anion exchange and hydrophobic interaction chromatography resins
Obviousness Reasoning
Combining complementary chromatography modes is a well-known strategy for improving protein separation efficiency, representing a routine optimization approach for a skilled practitioner
Source Patent Element
HIV-1 gp140 protein purification method
PTD Variation
Introducing buffer composition and pH optimization to minimize protein aggregation
Obviousness Reasoning
Controlling buffer conditions to improve protein stability is a standard technique in protein purification, representing a predictable refinement of existing separation processes
Source Patent Element
Multimodal resin-based protein capture
PTD Variation
Implementing multi-layer resin column with integrated UV detection
Obviousness Reasoning
Developing more sophisticated chromatography columns with enhanced analytical capabilities is a natural progression for improving protein purification technologies
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857619 and the disclosed variations, a Person Having Ordinary Skill In The Art would find the claimed innovations in protein purification techniques to be obvious extensions of existing multimodal chromatography methods, lacking the requisite non-obviousness for patent protection under 35 U.S.C. Section 103.

Original Patent Information

Patent NumberUS 11,857,619
TitleMultimodal chromatography method for the purification of HIV-1 envelope glycoprotein
Assignee(s)Janssen Vaccines & Prevention B.V.